Skip to main content
. 2018 Dec 11;22:336. doi: 10.1186/s13054-018-2277-5

Fig. 2.

Fig. 2

Temporal patterns in L-arginine and methylarginines over time in septic shock. Plasma L-arginine (a), asymmetric dimethylarginine (ADMA) (b) concentration changes over the first 7 days of inclusion in the VANISH trial; notation describes the number of samples available for analysis at each time point. Median and interquartile range plotted in red (both p < 0.001 over the time course (analysis of variance). Kaplan-Meier analysis of the association between methylarginine concentrations and outcome over time in septic shock following inclusion in the VANISH trial. A higher peak plasma ADMA (c) and symmetric dimethylarginine (SDMA) (d) concentration is associated with reduced survival in patients with septic shock. Data presented in quartiles (black line - top 25%, small-dotted grey line - 2nd quartile, dashed grey line - 3rd quartile, solid grey line - lowest quartile)